key: cord-0684407-zrg2gwfa
authors: Seppälä, Elina; Veneti, Lamprini; Starrfelt, Jostein; Danielsen, Anders Skyrud; Bragstad, Karoline; Hungnes, Olav; Taxt, Arne Michael; Watle, Sara Viksmoen; Meijerink, Hinta
title: Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021
date: 2021-09-02
journal: Euro Surveill
DOI: 10.2807/1560-7917.es.2021.26.35.2100793
sha: d6de1c38f269c7be408cfadaf565a48b77823621
doc_id: 684407
cord_uid: zrg2gwfa

Some variants of SARS-CoV-2 are associated with increased transmissibility, increased disease severity or decreased vaccine effectiveness (VE). In this population-based cohort study (n = 4,204,859), the Delta variant was identified in 5,430 (0.13%) individuals, of whom 84 were admitted to hospital. VE against laboratory confirmed infection with the Delta variant was 22.4% among partly vaccinated (95% confidence interval (CI): 17.0−27.4) and 64.6% (95% CI: 60.6−68.2) among fully vaccinated individuals, compared with 54.5% (95% CI: 50.4−58.3) and 84.4% (95%CI: 81.8−86.5) against the Alpha variant.

Since 2020, several variants of concern of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are associated with increased transmissibility, disease severity or potentially decreased vaccine effectiveness (VE) have been identified [1] . First detected in India in December 2020, the Delta variant (Phylogenetic Assignment of Named Global Outbreak (Pango) lineage designation B.1.617.2) was reported by 124 countries by the end of July 2021 and is expected to outcompete other currently circulating variants [2, 3] .

Preliminary reports suggest decreased VE against infection with the Delta variant compared with the Alpha variant, while VE against severe disease seems to be maintained [4, 5] . In order to understand the impact of the increased circulation of the Delta variant, and to inform policy on vaccination and non-pharmaceutical interventions in Norway, we estimated the effectiveness of coronavirus disease (COVID-19) vaccines against infection with the Delta variant compared with the Alpha variant in a population-based cohort study.

In Norway, the Delta variant was first identified in mid-April (week 15) 2021 and accounted for 67% of all sequenced samples by mid-July (week 28), overtaking the Alpha variant (B.1.1.7) as the dominating variant [6] . We obtained data on 19 August 2021 from BeredtC19, a national emergency preparedness registry established to monitor SARS-CoV-2 infection and the use of health services in Norway. The registry contains individual-level data from various Norwegian registries (Supplement, Table S1) [7] . We included all adults aged 18 years or older with a national identification number registered in Norway. We obtained data from 15 April to 15 August 2021 that were right-censored at a positive SARS-CoV-2 test (with or without sequencing), death or end of follow-up (15 August 2021) for this study [8] . We defined the outcome as infection with Delta or Alpha variant confirmed by PCR or by whole genome sequencing. The laboratory testing process for variants of SARS-CoV-2 in Norway has been described in detail elsewhere [6, 9] . We excluded individuals with prior SARS-CoV-2 infection, and those with an interval between first and second dose of a COVID-19 vaccine ( Table 1 ) that did not adhere to national recommendations. The official recommendation for time between doses in Norway is 12 weeks (minimum 21 days) for Comirnaty (BioNTech-Pfizer, Mainz, Germany/ New York, United States) and 12 weeks for Spikevax (minimum 28 days) (mRNA-1273, Moderna, Cambridge, United States) for immunocompetent individuals, while for immunocompromised individuals the recommended interval is 3 and 4 weeks, respectively [10] . Underlying conditions were categorised as 'high risk' or 'medium risk' as stipulated by the national vaccination programme (Supplement, part 1) [8] . Vaccination status was defined as: unvaccinated (unvaccinated and/ or < 21 days after first vaccine dose), partly vaccinated ( ≥ 21 days after first vaccine dose and/or < 7 days after second vaccine dose and fully vaccinated ( ≥ 7 days after second vaccine dose).

In total, we included 4,204,859 individuals of whom 32.4% (1,360,772) were partly vaccinated and 46.0% (1, 934, 912) were fully vaccinated at the end of follow-up. Characteristics of the study population are shown in Table 1 while the evolution of the epidemic and vaccination coverage is shown in Figure 1 

Using vaccination status as a time-dependent covariate, and explicit time to account for changes in the baseline hazard over time in a Cox proportional hazards model, we estimated the VE against infection with the Delta and Alpha variants, adjusting for factors which were associated with the likelihood of being vaccinated and being infected with the Alpha or Delta variant, namely age, sex, country of birth, county of residence and underlying comorbidities associated with increased risk of severe COVID-19 ( (Table 2) . Similarly, a separate analysis stratified by age (Supplement, part 4) showed that the VE against infection with the Delta variant for fully vaccinated individuals was significantly lower than against the Alpha variant, although data within each strata are limited and results should be interpreted with caution. As a sensitivity analysis, we kept all study participants, but excluded all days between the day of the first dose and 21 days after the first dose for each participant. This excluded all follow-up time (time at risk) and infections from the period where individuals had received the vaccine but were not yet considered partly vaccinated and may have had some protection. This approach slightly increased the overall VE estimates (Supplement, part 5).

By 15 August 2021, 84 (1.6%) of 5,430 individuals infected with the Delta variant were hospitalised with COVID-19 as the main diagnosis. Of these, 62 were 

Ethical approval was granted by Regional Committees for Medical and Health Research Ethics (REC) South East (reference number 122745).

The VE against infection was lower for the Delta variant compared with the Alpha variant among both partly and fully vaccinated individuals. Nevertheless, fully vaccinated individuals had lower risk of infection with the Delta (HR 0.35 (95% CI: 0.32-0.39)) and Alpha variant (HR 0.16 (0.13-0.18)) compared to unvaccinated individuals. This is in line with previous studies which have assessed vaccine effectiveness against symptomatic infections [4, 5, 11] . Our estimates of VE should, however, be interpreted with caution since they are based on observational data. In addition, comparisons with other studies should take into account different study designs, e.g. in our study we included both symptomatic and asymptomatic infections. Another point to keep in mind is that in Norway the main vaccines administered were the mRNA vaccines Comirnaty and Spikevax.

COVID-19 testing in Norway is not limited to symptomatic patients. It is available and free of charge for everyone including those with mild symptoms, close contacts and individuals in quarantine. Testing activity for SARS-CoV-2 is high and since January 2021, most reported cases have either been screened with a PCR variant assay or sequenced [9, 12] . Approximately 55% of reported cases have been screened successfully since January and 71% since April [6] . The testing strategy in Norway was enhanced from mid-February 2021, with increased contact tracing and more extensive testing during the period when the Alpha and Beta variants were more prevalent [9] . This testing strategy has facilitated the equal detection of all variants of SARS-CoV-2 and assisted in limiting bias in the comparison of VE against Alpha and Delta variants in our study.

Norway started COVID-19 vaccination on 27 December 2020, focusing on individuals over 65 years, health care workers, elderly people and individuals with increased risk of severe COVID-19 due to underlying comorbidities [13] (Supplement, part 1). From March 2021, parts of Oslo and other municipalities mainly in Viken county have been prioritised due to increased disease burden. By 15 August, 87% of the adult population aged 18 years or older had received one dose and 52% had received two doses, primarily of mRNA-vaccines [6] . The prioritisation of some groups has resulted in varying trends of vaccination uptake across counties, age and risk groups. While we have adjusted for this by including them as covariates in the Cox model, the impact of this imbalance could potentially bias the results. Furthermore, there have recently been reports of declining VE against infection over time [14] . Although our methods should adjust for changes in underlying risks over time, such a decline may confound our analysis and bias the VE against Delta downwards, as most infections with the Delta variant occurred towards the end of follow-up in our study.

The substantial difference in VE between partly and fully vaccinated individuals emphasises the importance of ensuring high coverage for the second dose to reduce transmission. At the same time, although protection against infection with the Delta variant is suboptimal after the first dose, other countries have reported high VE against severe outcomes (above 78% for the different types of vaccines) and reduced risk of severe disease with the Delta variant even after the first dose [5, 11] . The small number of hospital admissions and deaths related to the Delta variant among fully and partly vaccinated individuals in Norway support these reports of high VE against severe disease.

The proportions of individuals with severe outcomes (hospitalisation and/or death) in our study cannot be directly compared between variants because most Delta cases were diagnosed at the end of follow-up, and some of these cases may have developed severe disease after the end of follow-up. Additionally, the probability of vaccinated persons developing severe disease is confounded by the fact that a larger proportion of elderly people and people with underlying comorbidities are fully vaccinated, were vaccinated earliest and with the shortest interval between first and second dose.

Data on protection against infection and severe disease are crucial to guide future vaccination strategy. Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with both the Delta and Alpha variants appears to be considerable among fully vaccinated people in Norway. Suboptimal protection against infection after the first dose supports efforts to ensure high uptake for the second dose.

Stockholm: ECDC; 2021

Threat assessment brief: implications for the EU/EEA on the spread of the SARS-CoV-2 Delta (B.1.617.2) variant of concern. Stockholm: ECDC; 2021

Weekly epidemiological update on COVID-19 -20

Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant

Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

Ukerapporter om koronavirus og covid-19

Emergency preparedness register for COVID-19 (Beredt C19)

Who will get the coronavirus vaccine? Oslo: NIPH

Increased risk of hospitalisation and intensive care admission associated with infection with SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway

Effectiveness of COVID-19 vaccines against variants of concern in Ontario

Rapid SARS-CoV-2 variant monitoring using PCR confirmed by whole genome sequencing in a high-volume diagnostic laboratory

High vaccine effectiveness against COVID-19 infection and severe disease among residents and staff of long-term care facilities in Norway

New COVID-19 cases and hospitalizations among adults, by vaccination status

License, supplementary material and copyright

We wish to thank all those who have helped to collect, report and transfer data into the BeredtC19 national preparedness register at the Norwegian Institute of Public Health (NIPH) throughout the pandemic. We also acknowledge the efforts that regional laboratories have put into establishing a routine variant screening procedure or whole genome sequencing and registration of all analyses in national registries for surveillance. Thanks also to the staff at the virology and bacteriology departments at NIPH involved in national variant identification and whole genome analyses of SARS-CoV-2 viruses and in the cleaning of the data reported from all laboratories across the country. We would also like to acknowledge our colleagues at the NIPH who have contributed to the data cleaning from different registries and who provided their valuable input into the preparation in this manuscript.Funding: No specific funding received. The study was performed as part of routine work at the Norwegian Institute of Public Health.

None declared.